Core Scientific Creations (WoundClot)

**Product and the concrete problem it solves.** Core Scientific Creations (CSC), which markets its flagship product under the WoundClot brand, attacks one of the oldest and most lethal problems in both combat and civilian trauma: uncontrolled hemorrhage. Exsanguination remains the leading cause of preventable death on the battlefield and a major driver of mortality in pre-hospital civilian trauma, and the therapeutic window is measured in minutes. The incumbent field answer — pressure, tourniquets, and packing wounds with kaolin- or chitosan-impregnated gauze — works but has real limits: many procoagulant gauzes depend on the patient's own clotting cascade functioning normally, can generate heat, are difficult to reposition once applied, and clear poorly from deep or junctional wounds where a tourniquet cannot be placed. WoundClot's pitch is a next-generation hemostatic dressing engineered to be effective even in compromised-coagulation conditions, to adhere tenaciously to a bleeding site without rigid pressure, and to be safely absorbed by the body. In practical terms it is a single, lightweight consumable that a medic, first responder, or surgeon can pack into a wound to buy time and control bleeding that conventional gauze cannot.

**Core technology and how it actually works.** WoundClot is built from what the company describes as a Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) — a plant-derived cellulose engineered at the molecular level rather than a chemically oxidized cellulose (the chemistry behind classic surgical hemostats). When applied to a bleeding site the dry, flexible gauze rapidly converts into a thick, tenacious, expanding three-dimensional gel matrix that the company states can absorb up to roughly 2,500% of its weight in blood and remain actively absorbent for up to 24 hours. Mechanistically it works along two complementary paths: physically, the gel concentrates platelets, red blood cells, and clotting factors while adhering to surrounding tissue and resisting dislodgement from movement or pressure; and biochemically, the matrix is described as helping activate intrinsic-pathway clotting factors XI and XII. Because the material forms a molecular gel rather than relying solely on a functioning coagulation cascade, the company positions it as effective on anticoagulated or coagulopathic patients — a population that grows with age and blood-thinner use. The dressing is bioabsorbable, described as resorbing within about a week, which matters for surgical and internal applications where a mechanical gauze would have to be removed. The developer of the technology, Dr. Shani Eliyahu-Gross, is a nano-materials specialist, and the product line spans distinct Trauma, Surgical, EMS/First-Responder, hemodialysis, and Veterinary variants built on the same core matrix.

**Market, customers, and go-to-market.** WoundClot sells into the global hemostatic-agents and advanced-wound-care market, addressing military medicine, emergency medical services, law enforcement, hospital operating rooms, dialysis clinics, and even veterinary care. The go-to-market is a classic medical-device distribution model: CE marking and U.S. FDA 510(k) clearance open regulated markets, and the company sells through distributors — reportedly across 32 countries including Italy, India, Vietnam, the United Kingdom, Poland, Romania, and France — supplemented by a U.S. presence in Florida. Public pricing references have put a trauma dressing around $10 and surgical kits around $100, consistent with a high-volume consumable rather than a capital device. The economic attraction of this category is recurring, per-procedure consumption: hemostatic gauze is used and discarded, so adoption by a hospital system, an EMS agency, or a military medical corps converts into repeat demand. The commercial challenge is equally clear — this is a reference- and evidence-driven purchase in which entrenched, formulary-listed incumbents hold the default position.

**Traction, funding, and third-party validation.** The strongest external validation is regulatory and operational rather than financial. WoundClot Hemostatic Gauze holds FDA 510(k) clearance (K160679) indicated for the control of mild, moderate, and severe bleeding as well as operative, post-operative, and donor-site bleeding, and it is CE-marked and listed in the U.S. FDA's Global Unique Device Identification Database (GUDID). The company reports real-world use by military medics, first responders, and hospitals, including in Israel, and its Israeli-ecosystem profile is documented on Startup Nation Finder. On the financial side, disclosure is thin: CSC is privately held, was reported to be raising venture capital around 2018, and no reliable cumulative funding total, revenue, or headcount is publicly confirmable — directory estimates of employees range from roughly 7 to 24. An important calibration point for diligence: despite FDA/CE clearance and field use, WoundClot does not appear on the current U.S. Committee on Tactical Combat Casualty Care (CoTCCC) recommended-devices list, which as of recent guidance centers on kaolin-based Combat Gauze and chitosan gauzes — meaning WoundClot's military traction is real but sits outside the single most influential U.S. formulary gate.

**Founders and team background.** CSC was founded in 2012 by Yuval Yaskil, who serves as CEO and who came from an Israeli medical-supplies distribution background — relevant experience for a company whose success turns on regulated distribution and clinical adoption. Yaskil has described conceiving the concept years earlier, with the decisive impetus arriving in early 2012 when the U.S. Army's Institute of Surgical Research publicly signaled demand for exactly the kind of advanced hemostatic he had envisioned. The core technical differentiator was developed by Dr. Shani Eliyahu-Gross, a nano-materials specialist who serves as VP and CTO and is credited with the cellulose-matrix chemistry. The team is small and product-focused; the evident strength is deep materials-science and hemostasis expertise paired with distribution instincts, while the principal open questions are commercial scale-up depth, clinical-evidence generation, and the regulatory/formulary sophistication needed to break into the most defended military and hospital purchasing channels.

**Competitive dynamics.** WoundClot competes in a crowded, well-defended hemostatic market. (1) Against **Teleflex/Z-Medica QuikClot Combat Gauze** (kaolin), the CoTCCC first-line military standard, WoundClot must overcome an incumbent with formulary lock-in and extensive combat evidence. (2) Against **chitosan gauzes** — Celox (MedTrade) and ChitoGauze/HemCon — it competes on mechanism and on performance in anticoagulated patients. (3) Against classic **oxidized-cellulose surgical hemostats** such as Ethicon/J&J's Surgicel and fibrin sealants (including Israel's Omrix, now part of J&J), it competes in the operating room on handling and absorbency. (4) It also competes with plain gauze packing plus pressure, which remains cheap and ubiquitous. WoundClot's plausible edges are: (i) a distinct non-oxidized cellulose matrix that forms an adhesive gel and claims efficacy under compromised coagulation; (ii) very high absorbency and a tenacious, repositionable-adhesion profile; (iii) full bioabsorbability enabling surgical/internal use; and (iv) broad CE/FDA-cleared product variants. The countervailing reality is that hemostatic gauze is partly commoditized, switching costs favor incumbents, and comparative clinical evidence and formulary status — not lab absorbency figures — decide large military and hospital tenders.

**Defense, security, and resilience dual-use relevance.** WoundClot's dual-use character is unusually genuine and already fielded rather than aspirational. The identical consumable serves battlefield trauma care (junctional and deep-wound hemorrhage control where tourniquets fail), homeland-security and mass-casualty response, law-enforcement tactical medicine, and routine hospital surgery and dialysis. That civilian-military symmetry is the essence of dual-use: the product's defense relevance is a direct extension of its clinical function, not a bolt-on. Strategically it maps onto casualty-care resilience — improving survivability at the point of injury, which Israel's medical corps and allied militaries have prioritized as a driver of falling case-fatality rates — and onto supply-chain sovereignty, since an indigenous, exportable hemostatic gives Israel and allied forces a domestic option in a category otherwise dominated by U.S. incumbents. The honest calibration: WoundClot is a consumable medical device, not a weapons or ISR capability, and its uplift depends on clinical evidence and formulary adoption (notably CoTCCC) rather than on breakthrough physics.

**Growth stage, trajectory, and key diligence risks.** CSC reads as a **mid-stage** commercial medical-device company: founded in 2012, shipping FDA/CE-cleared product across a multi-variant line, distributing into dozens of countries, and fielded with military and civilian users — well past concept, but small, privately held, and not yet scaled to a large outcome. The trajectory an investor would want to see is conversion of niche field use into formulary wins and defensible clinical evidence. The key diligence risks are, first, **financial opacity** — funding, revenue, margins, and headcount are not publicly confirmable; second, **formulary and evidence gaps** — absence from the CoTCCC recommended list and limited public head-to-head clinical data cap military and hospital penetration; third, **commoditization and incumbency** — a partly commodity market with entrenched, evidence-backed competitors and real switching costs; fourth, **scale and team depth** — a small organization must fund expensive trials and regulatory/commercial expansion; and fifth, **regulatory/quality exposure** — as a bleeding-control device, adverse events, recalls, or indication limits carry outsized consequences. Progression would be evidenced by CoTCCC recommendation or comparable formulary adoption, published comparative clinical outcomes, disclosed distribution/revenue traction, and a credible capital base to fund it.